CD38-CART inhibits the growth of CD38-overexpressing mantle cell lymphoma (MCL), Waldenstrom’s macroglobulinemia (WM), NK/T-cell lymphoma (NKTCL), multiple myeloma (MM), and T-cell acute lymphoblastic leukemia (T-ALL) in vitro, and ATRA enhances a wide range of CD38-low expressing cancer cells’ CD38 expression and increases the therapeutic efficacy of daratumumab (CD38-targeting antibody) and CD38-CART (Wang X. et al., 2022). Here, CD38 is linked to mantle cell lymphoma.